Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake

Andrew Fesler; Ga-Ram Hwang; Jingfang Ju

doi:10.1016/j.gendis.2022.11.020

您当前的位置：

首页 >

文章列表页 >

Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake

Short communication | 更新时间：2024-02-04

- Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake
- Genes & Diseases Vol. 1, Issue 1, Pages: 23-25(2024)
- 作者机构：
  
  1. Curamir Therapeutics Inc., Woburn,MA,USA,01801
  2. Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook,NY,USA,11794
  3. The Northport Veteran's Administration Medical Center, Northport,NY,USA,11768
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.11.020
  CLC：
- Published：2024，
  
  Published Online：1 January 2024，
扫描看全文
Andrew Fesler, Ga-Ram Hwang, Jingfang Ju. Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake. [J]. Genes & Diseases 1(1):23-25(2024)
DOI：

Andrew Fesler, Ga-Ram Hwang, Jingfang Ju. Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake. [J]. Genes & Diseases 1(1):23-25(2024) DOI： 10.1016/j.gendis.2022.11.020.

摘要

Abstract

关键词

Keywords

references

1 Y. Tsujimoto, J. Cossman, E. Jaffe, et al.Involvement of the bcl-2 gene in human follicular lymphoma Science, 228 (4706) (1985), pp. 1440-1443

2 A.W. Roberts, D. HuangTargeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies Clin Pharmacol Ther, 101 (1) (2017), pp. 89-98

3 P.V. DanenbergThymidylate synthetase - a target enzyme in cancer chemotherapy Biochim Biophys Acta, 473 (2) (1977), pp. 73-92

4 S. Purser, P.R. Moore, S. Swallow, et al.Fluorine in medicinal chemistry Chem Soc Rev, 37 (2) (2008), pp. 320-330

5 H. Zhang, Y. Nakauchi, T. Köhnke, et al.Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia Nat Cancer, 1 (8) (2020), pp. 826-839

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools